Rucaparib Receives Breakthrough Therapy Designation from FDA
Rucaparib Receives Breakthrough Therapy Designation from FDA
(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment … Continued